BeStock  
Stocks › Biotechnology › PBLS

Parabilis Medicines PBLS

US equityMarket cap rank #2333Biotechnology
$27.44 −$0.19 (-0.67%)
Market closed · Nov 21, 9:10 am ET · Last extended-hours $27.44 0.00%
Open$27.07
Prev close$27.63
Day range$26.50 – $28.52
Volume1.25M
Market cap$3.44B
P/E (TTM)–
Dividend yield–

PBLS Stock News

Headlines matching Parabilis Medicines or the PBLS ticker, most recent first.

  • Analysts Offer Insights on Healthcare Companies: Evolus (EOLS), Parabilis Medicines, Inc. (PBLS) and Acumen Pharmaceuticals (ABOS)TipRanks · 17 Sep 2026 · Direct mention
  • BofA Securities Maintains Parabilis Medicines(PBLS.US) With Buy Rating, Announces Target Price $45Market news · 17 Sep 2026 · Direct mention
  • Guggenheim Sticks to Its Buy Rating for Parabilis Medicines, Inc. (PBLS)TipRanks · 17 Aug 2026 · Direct mention
  • Analysts Offer Insights on Healthcare Companies: Neumora Therapeutics, Inc. (NMRA), Celcuity (CELC) and Parabilis Medicines, Inc. (PBLS)TipRanks · 15 Aug 2026 · Direct mention
  • Analysts Are Bullish on Top Healthcare Stocks: Parabilis Medicines, Inc. (PBLS), Cormedix (CRMD) PositiveTipRanks · 14 Aug 2026 · Direct mention
  • LifeSci Capital Maintains Parabilis Medicines(PBLS.US) With Buy Rating, Maintains Target Price $42Market news · 14 Aug 2026 · Direct mention
  • BofA Securities Maintains Parabilis Medicines(PBLS.US) With Buy RatingMarket news · 14 Aug 2026 · Direct mention
  • A Quick Look at Today's Ratings for Parabilis Medicines(PBLS.US), With a Forecast Between $40 to $45Market news · 7 Jul 2026 · Direct mention
  • Analysts Offer Insights on Healthcare Companies: Parabilis Medicines, Inc. (PBLS) and LENZ Therapeutics (LENZ)TipRanks · 6 Jul 2026 · Direct mention
  • LifeSci Capital Initiates Parabilis Medicines(PBLS.US) With Buy Rating, Announces Target Price $42Market news · 18 Jul 2026 · Direct mention
  • Parabilis Medicines, Inc. (PBLS) Receives a Buy From LifeSci CapitalTipRanks · 13 Jul 2026 · Direct mention
  • CCORF Initiates Parabilis Medicines(PBLS.US) With Buy Rating, Announces Target Price $39Market news · 9 Nov 2026 · Direct mention
  • CCORF Maintains Parabilis Medicines(PBLS.US) With Buy Rating, Maintains Target Price $39Market news · 13 Nov 2026 · Direct mention
  • H.C. Wainwright Maintains Parabilis Medicines(PBLS.US) With Buy Rating, Maintains Target Price $40Market news · 13 Nov 2026 · Direct mention
  • H.C. Wainwright Maintains Parabilis Medicines(PBLS.US) With Buy Rating, Maintains Target Price $40Market news · 26 Oct 2026 · Direct mention

Discussion

No comments yet — be the first to weigh in on PBLS.

Sign in to join the discussion.

Scroll to Top